Coronavirus briefing: Astra Zeneca resumes vaccine trial
Coronavirus briefing: Astra Zeneca resumes vaccine trial

The epidemic

  • Global cases have risen slightly over the week. India continues to account for the most recorded cases. Data from Latin America, the Middle East, and North Africa show some signs of improvement.
  • Cases, deaths, and hospitalisations still trended down in the US.
  • Cases have continued to climb in the EU, led by France and Spain. UK cases have also picked up. Hospital data shows that Europe’s outbreaks remain less serious than last spring, however.
  • This has led to speculation of a milder virus. There’s no scientific evidence of this so far, however. The median age among the infected and more testing plays into mortality figures.
  • Daily cases rose slightly in Sweden at the end of the week. However, testing had picked up. Cases continued to climb in Denmark and have risen slightly in Norway and, to a lesser extent, Finland. Hospitalisations in the Nordics have remained low and stable, however.
  • Daily cases have continued to increase in Lithuania and Estonia.
  • According to an Icelandic study, 9 out of 10 people infected with coronavirus would produce antibodies. The study indicates that this protected them from reinfection at least during 4 months.

Policy

  • The vaccine trial run by Astra-Zeneca and Oxford University will now be resumed. The trial was paused a week ago after one participant developed serious symptoms.
  • Several European countries have increased restrictions, but not strict lockdowns. In the UK, gatherings were limited to six people, for example. Austria also added limitations.
  • Israel installed a second lockdown due to a resurgence in cases.
  • Finland, Estonia, and Lithuania increased their threshold for quarantine-free border crossings to 25 cases per 100k people. Finland now allows free travel from Sweden, for example. In Finland, travellers from risk countries will also soon be allowed to shorten their quarantine time by testing.
  • The ECB made no changes to its formal policy at its meeting and communicated no big worry about inflation or strong currency, read more here.

Economic effects

  • Growth in German industrial production disappointed in July.
  • Chinese exports surprised on the upside again in August, supported by pandemic-related goods.
  • In Sweden, both the July data on production value and household consumption signalled a solid recovery. Industrial orders also continued up.
 
PDF-Document Read the full analysis/report here (pdf)


Maija Kaartinen 
Economist 
Swedbank AB (publ) 
SE-105 34 Stockholm 
Phone: +46 8 700 92 73 
research.swedbank.se 


Subscribe »
This letter is distributed by Swedbank in cooperation with Brightly. The letter is personal.
You need Adobe Acrobat Reader to show PDF documents. (download here)